Georgie Huggett

May 1, 2024

Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer—a study protocol for a randomised controlled trial

Abstract Background: Distressing symptoms are common in advanced cancer. Medicinal cannabinoids are commonly prescribed for a variety of symptoms. There…

October 14, 2023

Exploring potential anti-inflammatory effects of medicinal cannabis

Abstract Purpose: Inflammation is thought to play a key role in malignant disease and may play a significant part in…

September 5, 2022

Using a qualitative sub-study to inform the design and delivery of randomised controlled trials on medicinal cannabis for symptom relief in patients with advanced cancer

Abstract Background: Recruitment for randomised controlled trials in palliative care can be challenging; disease progression and terminal illness underpin high…